Although there are treatments available, none of them "cure" advanced renal cell carcinoma or cancer that has spread from the initial tumour.
But they can help extend a patients' life by around five to six months.
The drugs which also go by the names Avastin (bevacizumab), Nexavar (sorafenib), Sutent (sunitinib) and Torisel (temsirolimus) were found by the National Institute of Health and Clinical Excellence (NICE) to provide "significant gains" in survival.
However, further analysis showed they did not meet NICE criteria for "cost-effectiveness".
The NHS in Scotland has already advised against the use of three of the drugs, and an application has never been made for temsirolimus. A decision has yet to be taken in Northern Ireland.
The draft guidelines for England and Wales, which are subject to appeal, recommended people already on the drugs should be able to continue therapy.
Pat Hanlon from Kidney Cancer UK says the treatment provides a 'considerable benefit'.
Charities and some experts expressed outrage at the decision, saying it left patients only one treatment option - interferon - to which many do not respond.
Professor John Wagstaff, from the South Wales Cancer Institute, said there was "no point" in him accepting referrals for people with advanced kidney cancer as around 75% of them "do not gain any real benefit" from interferon.
The only other option was to make patients comfortable in their last months of life.
Professor Peter Johnson, from Cancer Research UK, said the drugs had shown a small but definite improvement in an illness where there are few alternative treatments.
This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.